Brief: Ars Pharmaceuticals Receives FDA Approval To Remove Age Requirement From Neffy® 1 Mg (Epinephrine Nasal Spray) Label
27/03/2026 12:07
ARS Pharmaceuticals Inc SPRY.O: ARS PHARMACEUTICALS RECEIVES FDA APPROVAL TO REMOVE AGE REQUIREMENT FROM NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) LABEL Source text: ID:nGNX7Knd3h Further company coverage: SPRY.O
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle